Cargando…
Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy
OBJECTIVE: The purpose of this study was to determine the efficacy and tolerability of hemithoracic radiotherapy implemented with helical tomotherapy (HTT) in malignant pleural mesothelioma (MPM) patients. METHODS: Between October 2018 and December 2020, data from 11 MPM patients who received trimod...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kare Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170385/ https://www.ncbi.nlm.nih.gov/pubmed/37181055 http://dx.doi.org/10.14744/nci.2023.53896 |
_version_ | 1785039217034788864 |
---|---|
author | Ozyurt, Hazan Ozdemir, Sevim Dogan, Bedriye Gunalp, Gun Ozden, Ayse Sevgi |
author_facet | Ozyurt, Hazan Ozdemir, Sevim Dogan, Bedriye Gunalp, Gun Ozden, Ayse Sevgi |
author_sort | Ozyurt, Hazan |
collection | PubMed |
description | OBJECTIVE: The purpose of this study was to determine the efficacy and tolerability of hemithoracic radiotherapy implemented with helical tomotherapy (HTT) in malignant pleural mesothelioma (MPM) patients. METHODS: Between October 2018 and December 2020, data from 11 MPM patients who received trimodality therapy, including lung-sparing surgery (pleurectomy-decortication, P/D), adjuvant chemotherapy (cisplatin+ pemetrexed), and radiotherapy, were retrospectively reviewed. HTT was used to deliver a total of 30 Gy, 50–54 Gy or 59.4–60 Gy to R2 disease with 1.8–2 Gy daily doses. Descriptive data are presented in number (percentage) or median (minimum– maximum). The Kaplan-Meier method was used to calculate survival data. In patients with toxicities, the risk organ doses were compared using the Mann-Whitney U test. RESULTS: The median follow-up was 20.5 (12–30) months. Two-year local control, disease-free, and overall survival rates were 48.5%, 49%, and 77.9%, respectively. The median prescribed dose for planning target volume (PTV) was 50.4±8.7 (30–60) Gy. Mean dose (D(mean)) of total lung was 19.9±6 (10.4–26) Gy; the V20 (%) of ipsilateral and contralateral lungs were 89.±11.2 (62.7–100) and 0.7±2.1 (0.49–5.9), respectively. Esophageal D(mean) and maximum doses (D(max)) were found as 21.7±8.4 (7.4–34) and 53.1±10.4 (25.4–64.4) Gy, respectively. V30 (%) and Dmean of heart were 22.3%±13.4% (3.9–47) and 21±5.7 (10.8–29.3) Gy, respectively. D(max) of medulla spinalis (MS) was 38.6± 1.3 (13.7–48) Gy. Grade 1–2 radiation pneumonitis (RP) developed in 4 (36.4%) and esophagitis in 2 (18.2%) patients. RP was found to be associated with MS and esophageal doses (p<0.05). Myelitis was diagnosed in 1 (9.1%) patient (MS D(max): 29 Gy). CONCLUSION: HTT can be used as part of trimodality therapy for MPM patients with acceptable toxicities. MS and esophageal doses should be considered for radiation pneumonitis risk, and new dose constraints for these organs should be defined. |
format | Online Article Text |
id | pubmed-10170385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Kare Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-101703852023-05-11 Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy Ozyurt, Hazan Ozdemir, Sevim Dogan, Bedriye Gunalp, Gun Ozden, Ayse Sevgi North Clin Istanb Orıgınal Article OBJECTIVE: The purpose of this study was to determine the efficacy and tolerability of hemithoracic radiotherapy implemented with helical tomotherapy (HTT) in malignant pleural mesothelioma (MPM) patients. METHODS: Between October 2018 and December 2020, data from 11 MPM patients who received trimodality therapy, including lung-sparing surgery (pleurectomy-decortication, P/D), adjuvant chemotherapy (cisplatin+ pemetrexed), and radiotherapy, were retrospectively reviewed. HTT was used to deliver a total of 30 Gy, 50–54 Gy or 59.4–60 Gy to R2 disease with 1.8–2 Gy daily doses. Descriptive data are presented in number (percentage) or median (minimum– maximum). The Kaplan-Meier method was used to calculate survival data. In patients with toxicities, the risk organ doses were compared using the Mann-Whitney U test. RESULTS: The median follow-up was 20.5 (12–30) months. Two-year local control, disease-free, and overall survival rates were 48.5%, 49%, and 77.9%, respectively. The median prescribed dose for planning target volume (PTV) was 50.4±8.7 (30–60) Gy. Mean dose (D(mean)) of total lung was 19.9±6 (10.4–26) Gy; the V20 (%) of ipsilateral and contralateral lungs were 89.±11.2 (62.7–100) and 0.7±2.1 (0.49–5.9), respectively. Esophageal D(mean) and maximum doses (D(max)) were found as 21.7±8.4 (7.4–34) and 53.1±10.4 (25.4–64.4) Gy, respectively. V30 (%) and Dmean of heart were 22.3%±13.4% (3.9–47) and 21±5.7 (10.8–29.3) Gy, respectively. D(max) of medulla spinalis (MS) was 38.6± 1.3 (13.7–48) Gy. Grade 1–2 radiation pneumonitis (RP) developed in 4 (36.4%) and esophagitis in 2 (18.2%) patients. RP was found to be associated with MS and esophageal doses (p<0.05). Myelitis was diagnosed in 1 (9.1%) patient (MS D(max): 29 Gy). CONCLUSION: HTT can be used as part of trimodality therapy for MPM patients with acceptable toxicities. MS and esophageal doses should be considered for radiation pneumonitis risk, and new dose constraints for these organs should be defined. Kare Publishing 2023-03-28 /pmc/articles/PMC10170385/ /pubmed/37181055 http://dx.doi.org/10.14744/nci.2023.53896 Text en © Copyright 2023 by Istanbul Provincial Directorate of Health https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Orıgınal Article Ozyurt, Hazan Ozdemir, Sevim Dogan, Bedriye Gunalp, Gun Ozden, Ayse Sevgi Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy |
title | Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy |
title_full | Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy |
title_fullStr | Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy |
title_full_unstemmed | Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy |
title_short | Trimodality therapy of malignant pleural mesothelioma with helical tomotherapy |
title_sort | trimodality therapy of malignant pleural mesothelioma with helical tomotherapy |
topic | Orıgınal Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170385/ https://www.ncbi.nlm.nih.gov/pubmed/37181055 http://dx.doi.org/10.14744/nci.2023.53896 |
work_keys_str_mv | AT ozyurthazan trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy AT ozdemirsevim trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy AT doganbedriye trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy AT gunalpgun trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy AT ozdenaysesevgi trimodalitytherapyofmalignantpleuralmesotheliomawithhelicaltomotherapy |